Preimplantation Genetics Diagnosis (PGD) Market Global Scenario, Market Size, Outlook, Trend, and Forecast, 2016 – 2025

Global Preimplantation Genetics Diagnosis (PGD) Market size is projected to be valued $140 Million by 2024; with a CAGR of 6.2% from 2017 to 2025. Preimplantation genetic diagnosis (PGD) also referred as embryo screening, is a branch of genetics involves in genetic testing of embryo through In-Vitro fertilization (IVF). Preimplantation genetics diagnosis enables to identify defects in embryos and aids in selecting health embryos that are further used for implanting in the uterus. This technique can selectively avoid the passing of hereditary disorders that prevails in the family into a newborn baby.

Declining fertility rate globally, development of advanced technologies in the field of genetic analysis, and growing occurrence of genetic disorders are the drivers boosting the growth of the global preimplantation genetics diagnosis market. Moreover, increasing rate in the adoption of IVF, and rising possibility of genetic abnormalities in embryos with progressing maternal age also supports the growth of the market. However, stringent government regulations, and social-economic concerns would severally hamper the adoption among end users. Furthermore, increasing R&D and market expansion would provide future scope for the market in the coming years.

The global preimplantation genetics diagnosis (PGD) is segmented on the basis of test type and geography. Test type is further bifurcated as gender selection, chromosomal abnormalities, single gene disorders, HLA typing, aneuploidy, X-linked diseases, and other types.

Based on geography, global market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is further bifurcated in U.S., Canada and Mexico whereas Europe consist of UK, Germany, France, and others. Asia-Pacific is segmented into India, China, Japan, and others, while RoW is bifurcated into South America, Middle East and Africa.

The key market players include Abbott Laboratories, Natera, Inc., PerkinElmer, Inc., Illumina, Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Cooper Surgical, Inc., and Beijing Genomics Institute (BGI), among others.

The report covers

• The detailed analysis of Preimplantation Genetics Diagnosis (PGD) Market with respect to key segments such as test type, and geography has been included in the report
• The report comprises the qualitative and quantitative analysis of the market with market estimation over 2016 – 2025 and CAGR between 2017 and 2025
• Comprehensive analysis of market dynamics including growth factors, restraining factors and opportunities will be provided in the report
• An exhaustive regional and country wise analysis of Preimplantation Genetics Diagnosis (PGD) Market has been covered in the report
• Profile of the major key players operating in the Preimplantation Genetics Diagnosis (PGD) Market will be provided, with detailed study on their key financials, product & services, new developments and business strategies

Scope of the Global Preimplantation Genetics Diagnosis (PGD) Market

Test Type Segments

• Gender Selection
• Chromosomal Abnormalities
• Single Gene Disorders
• HLA Typing
• Aneuploidy
• X-Linked Diseases
• Other Test Types

Geography Segments

• North America
• U.S.
• Canada
• Mexico

• Europe
• UK
• Germany
• France
• Others

• Asia-Pacific
• China
• Japan
• India
• Others
• RoW
• South America
• Middle East
• Africa